The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death

Neurochemistry International

Volumn 50, Issue 3, 2007, Pages 555-563

  Vegh, Miklos G ^a   Kovács, Attila D ^a   Kovács, Gábor ^a   Szabó, Géza ^a   Tihanyi, Károly ^a   Hársing Jr , László G ^a   Lévay, György ^a,b  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

AMPA; Benzodiazepine; GluR1; Kainate; Neuroprotection; NMDA; Primary neuronal culture; Purkinje neuron; Stereoselectivity

Indexed keywords

1 (4 AMINOPHENYL) 7,8 METHYLENEDIOXY 4 CYANO 4 METHYL 3 N ACETYL 5H 3,4 DIHYDRO 2,3 BENZODIAZEPINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; BENZODIAZEPINE DERIVATIVE; CARBON; EGIS 8332; GLUTAMATE RECEPTOR 1; ION CHANNEL; IONOTROPIC RECEPTOR; KAINIC ACID; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR AGONIST; LACTATE DEHYDROGENASE; METHYL GROUP; N METHYL DEXTRO ASPARTIC ACID; NITRILE; QUISQUALIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DEATH; CHO CELL; CONTROLLED STUDY; EMBRYO; ENANTIOMER; ENZYME RELEASE; EVOKED RESPONSE; IC 50; NERVE CELL CULTURE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PURKINJE CELL; RAT; STEREOCHEMISTRY; TELENCEPHALON;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BENZODIAZEPINES; CELL DEATH; CELLS, CULTURED; EXCITATORY AMINO ACID ANTAGONISTS; MALE; NEURONS; QUISQUALIC ACID; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; STEREOISOMERISM; TELENCEPHALON;

RATTUS;

EID: 33846671081     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.11.003     Document Type: Article

References (65)

1. Ábrahám G., Sólyom S., Csuzdi E., Berzsenyi P., Ling I., Tarnawa I., Hámori T., Pallagi I., Horváth K., Andrási F., Kapus G., Hársing Jr. L.G., Király I., Patthy M., and Horváth G. New non competitive AMPA antagonists. Bioorg. Med. Chem. 8 (2000) 2127-2143
2. Barkóczy J., Bertha F., Fetter J., Ling I., and Simig G. Synthesis of enantiomers of EGIS-8332. Proceedings of the XXI European Colloquium on Heterocyclic Chemistry. Sopron, Hungary, September 12-15 (2004) Abstract no. MP-08
3. Benveniste H., Drejer J., Schousboe A., and Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43 (1984) 1369-1374
4. Bernard V., Gardiol A., Faucheux B., Bloch B., Agid Y., and Hirsch E.C. Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion. J. Comp. Neurol. 368 (1996) 553-568
5. Blandini F., Porter R.H., and Greenamyre J.T. Glutamate and Parkinson's disease. Mol. Neurobiol. 12 (1996) 73-94
6. Bleakman D., Ballyk B.A., Schoepp D.D., Palmer A.J., Bath C.P., Sharpe E.F., Woolley M.L., Bufton H.B., Kamboj R.K., Tarnawa I., and Lodge D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology 35 (1996) 1689-1702
7. Bleakman D., Schoepp D.D., Ballyk B.A., Bufton H.B., Sharpe E.F., Thomas K., Ornstein P.L., and Kamboj R.K. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3 -carboxylic acid. Mol. Pharmacol. 49 (1996) 581-585
8. Bliss T.V.P., and Collingridge G.L. A synaptic model of memory: long term potentiation in the hippocampus. Nature 361 (1993) 31-39
9. Bond A., Lodge D., Hicks C.A., Ward M.A., and O'Neill M.J. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischemic tolerance in the gerbil hippocampus. Eur. J. Pharmacol. 380 (1999) 91-99
10. Breese C.R., Logel J., Adams C., and Leonard S.S. Regional gene expression of the glutamate receptor subtypes GluR1, GluR2, and GluR3 in human postmortem brain. J. Mol. Neurosci. 7 (1996) 277-289
11. Brott T., and Bogousslavsky J. Treatment of acute ishemic stroke. New Engl. J. Med. 343 (2000) 710-722
12. Buchan A.M., Li H., and Pulsinelli W.A. The N-methyl-d-aspartate antagonist, MK-801, fails to protect against neuronal damage caused by transient, severe forebrain ischemia in adult rats. J. Neurosci. 11 (1991) 1049-1056
13. Buchan A.M., Lesiuk H., Barnes K.A., Li H., Huang Z.G., Smith K.E., and Xue D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?. Stroke 24 12 Suppl. (1993) I148-I152
14. Cebers G., Zhivotovsky M., Ankarcrona M., and Liljequist S. AMPA neurotoxicity in cultured cerebellar granule neurons: mode of cell death. Brain Res. Bull. 43 (1997) 393-403
15. Chapman A.G., Smith S.E., and Meldrum B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466 in mice. Epilepsy Res. 9 (1991) 92-96
16. Cheung N.S., Pascoe C.J., Giardina S.F., John C.A., and Beart P.M. Micromolar l-glutamate induces extensive apoptosis in an apoptotic-necrotic continuum of insult-dependent, excitotoxic injury in cortical neurons. Neuropharmacology 37 (1998) 1419-1429
17. Collingridge G.L., and Lester R.A. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 41 (1989) 143-210
18. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
19. Donevan S.D., and Rogawski M.A. GYKI 52466 a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10 (1993) 51-59
20. Emerich D.F. Neuroprotective possibilities for Huntington's disease. Exp. Opin. Biol. Ther. 1 (2001) 467-479
21. Garyfallou V.T., Kohama S.G., and Urbanski H.F. Distribution of NMDA and AMPA receptors in the cerebellar cortex of rhesus macaques. Brain Res. 716 (1996) 22-28
22. Gigler G., Simó A., and Lévay G. EGIS-8332, a new non-competitive AMPA antagonist with neuroprotective and anticonvulsive activities. J. Cereb. Blood Flow Metab. 19 Suppl. 1 (1999) S150
23. Gitto R., Orlando V., Quartarone S., De-Sarro G., De-Sarro A., Russo E., Ferreri G., and Chimirri A. Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives. J. Med. Chem. 46 (2003) 3758-3761
24. Gyertyán I., Gigler G., and Simó A. The neuroprotective and hypothermic effect of GYKI 52466, a non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist on histological and behavioural variables in the gerbil global ischemia model. Brain Res. Bull. 50 (1999) 179-186
25. Hwang J.Y., Kim Y.H., Ahn Y.H., Wie M.B., and Koh J.Y. N-Methyl-d-aspartate receptor blockade induces neuronal apoptosis in cortical culture. Exp. Neurol. 159 (1999) 124-130
26. Jiang X., Zhu D., Okagaki P., Lipsky R., Wu X., Banaudha K., Mearow K., Strauss K.I., and Marini A.M. N-Methyl-d-aspartate and TrkB receptor activation in cerebellar granule cells: an in vitro model of preconditioning to stimulate intrinsic survival pathways in neurons. Ann. N.Y. Acad. Sci. 993 (2003) 134-145
27. Kapus G., Kertész S., Giegler G., Simo A., Vegh M., Barkóczy J., Harsing L.G., Szabó G., and Lévay G. Comparison of the AMPA antagonist action of the 2,3-benzodiazepines in vitro and their neuroprotective effects in vivo. Pharmacol. Res. 21 (2004) 317-323
28. Kimura M., Katayama K., and Nishizawa Y. Role of glutamate receptors and voltage-dependent calcium channels in glutamate toxicity in energy-compromised cortical neurons. Jpn. J. Pharmacol. 80 (1999) 351-358
29. Koek W., Wood J.H., and Winger G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission produces phenylcyclidine-like behavioural effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245 (1988) 969-974
30. Kovács A.D., and Egyed A. Protection against non-NMDA receptor-mediated exitotoxicity by GYKI 52466 in mature telencephalic cultures of the rat. Neurobiology 4 (1996) 59-72
31. Kovács A.D., Gigler G., Szücs Zs., Gacsályi G., Szabados T., and Szabó G. In vitro and in vivo effects of some non-competitive AMPA antagonist 2,3-benzodiazepines (GYKI 52466-HCl, 53405, 53655). Biochem. Soc. Trans. 5665 (1996) E31
32. Kovács A.D., and Szabó G. Comparison of neuroprotective efficacy of competitive and non-competitive AMPA antagonists in vitro. Environ. Toxicol. Pharmacol. 3 (1997) 69-72
33. Kovács A.D., and Szabó G. GYKI 53655, a 2,3-benzodiazepine non-competitively protects cultured neurons against AMPA toxicity. Eur. J. Pharmacol. 331 (1997) 93-96
34. Lazzaro J.T., Paternain A.V., Lerma J., Chenard B.L., Ewing F.E., Huang J., Welch W.M., Ganong A.H., and Menniti F.S. Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 42 (2002) 143-153
35. Lee H.G., Zhu X., Ghanbari H.A., Ogawa O., Raina A.K., O'Neill M.J., Perry G., and Smith M.A. Differential regulation of glutamate receptors in Alzheimer's disease. Neurosignals 11 (2002) 282-292
36. Lees G.J. Pharmacology of AMPA/kainate receptor ligands and their therapeutical potential in neurological and psychiatric disorders. Drugs 59 (2000) 33-78
37. Le Peillet E., Arvin B., Moncada C., and Meldrum B.S. The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res. 571 (1992) 115-120
38. Lodge D., Bond A., O'Neill M.J., Hicks C.A., and Jones M. Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology 35 (1996) 1681-1688
39. Matucz E., Móricz K., Gigler G., Simó A., Barkóczy J., Lévay G., Hársing Jr. L.G., and Szénási G. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia. Brain Res. 1019 (2004) 210-216
40. Menniti F.S., Buchan A.M., Chenard B.L., Critchett D.J., Ganong A.H., Guanowski G., Seymour P.A., and Welch W.M. CP-465,022, a selective, noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 34 (2003) 171-176
41. Nellgard B., Gustafson I., and Wieloch T. Lack of protection by the N-methyl-d-aspartate receptor blocker dizocilpine (MK-801) after transient severe cerebral ischemia in the rat. Anesthesiology 75 (1991) 279-287
42. Nellgard B., and Wieloch T. Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia. J. Cereb. Blood Flow Metab. 12 (1992) 2-11
43. Nishimura M., Sato K., Okada T., Yoshiya I., Schloss P., and Shimada S. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88 (1998) 768-774
44. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., and Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34 (1995) 1239-1258
45. Pelletier J.C., Hesson D.P., Jones K.A., and Costa A.M. Substituted 1,2-dihydrophtalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem. 39 (1996) 343-346
46. Rammes G., Swandulla D., Collingridge G.L., Hartmann S., and Parsons C.G. Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurons and area CA1 in hippocampal slices. Br. J. Pharmacol. 117 (1996) 1209-1221
47. Rátkai Z., et al. New 7,8-dihydro-8,8-disubstituted-9H-1,3-dioxolo-[4,5-h][2,3]-benzodiazepine derivatives, pharmaceutical compositions containing them as active component, and process for producing them. HU Appl. 97/01381 (1997)
48. Savic I., Thomas A.M., Ke Y., Curran J., Fried I., and Engel J. In vivo measurements of glutamine + glutamate and N-acetyl aspartate levels in human partial epilepsy. Acta Neurol. Scand. 102 (2000) 179-188
49. Seeburg P.H. The molecular biology of mammalian glutamate receptor channels. Trends Pharmacol. Sci. 14 (1993) 291-303
50. Seeburg P.H., Higuchi M., and Sprengel R. RNA editing of brain glutamate receptor channels: mechanism and physiology. Brain Res. Rev. 26 (1998) 217-229
51. Sheardown M., Suzdak P.D., and Nordholm l. AMPA, but not NMDA receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h. Eur. J. Pharmacol. 236 (1993) 347-353
52. Sólyom S., and Tarnawa I. Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharm. Des. 8 (2002) 913-939
53. Spedding M., Gressens P., Villa P., Medja P., Williamson T., Gigler G., Kertész S., Kapus G., Levay G., Szenasi G., Barkóczy J., and Harsing L.G. The effects of AMPA antagonists in models of stroke and neurodegeneration. Program No. 895.10.2003. Abstract Viever/Itinerary Planner (2003), Society for Neuroscience, Washington, DC Online
54. Szabó G., and Henley J.M. Binding of the AMPA receptor antagonists [3H]GYKI 53405 to Xenopus brain membranes. Neuroreport 5 (1993) 93-94
55. Tarnawa I., Farkas S., Berzsenyi P., Pataki A., and Andrasi F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant GYKI 52466. Eur. J. Pharmacol. 167 (1989) 193-199
56. Tarnawa I., and Vizi E.S. 2,3-Benzodiazepine AMPA antagonists. Restor. Neurol. Neurosci. 13 (1998) 41-57
57. Tomiyama M., Palacios J.M., Cortes R., and Mengod G. Flip and flop variants of AMPA receptor subunits in the human cerebellum: implication for the selective vulnerability of Purkinje cells. Synapse 31 (1999) 163-167
58. Vizi E.S., Mike A., and Tarnawa I. 2, 3-Benzodiazepines (GYKI 52466 and analogs): negative allosteric modulators of AMPA receptors. CNS Drug Rev. 2 (1996) 91-126
59. Vizi E.S., Mike A., and Tarnawa I. The functional study of kainate receptors-hopes and doubts. Trends Neurosci. 20 (1997) 396
60. Wenk G.L., Danysz W., and Mobley S.L. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. 293 (1995) 267-270
61. Wilding T.J., and Huettner J.E. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines. Mol. Pharmacol. 47 (1995) 582-587
62. Wisden W., and Seeburg P.H. A complex mosaic of high-affinity kainate receptors in rat brain. J. Neurosci. 13 (1993) 3582-3598
63. Xue D., Huang Z.-G., Barnes K., Lesiuk H.J., Smith K.E., and Buchan A.M. Delayed treatment with AMPA, but not with NMDA, antagonists reduces neocortical infarction. J. Cereb. Blood Flow Metab. 14 (1994) 251-261
64. Zhao H.M., Wenthold R.J., Wang Y.X., and Petralia R. δ-Glutamate receptors are differently distributed at parallel and climbing fiber synapses on Purkinje cells. J. Neurochem. 68 (1997) 1041-1052
65. Zorumski C.F., Yamada K.A., Price M.T., and Olney J.W. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron 10 (1993) 61-67